Pulse Biosciences, Inc. (PLSE) — SEC Filings
Pulse Biosciences, Inc. (PLSE) — 50 SEC filings. Latest: 8-K (May 6, 2026). Includes 37 8-K, 6 10-Q, 3 DEF 14A.
View Pulse Biosciences, Inc. on SEC EDGAR
Overview
Pulse Biosciences, Inc. (PLSE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 16, 2026: On April 16, 2026, Pulse Biosciences, Inc. filed an 8-K report detailing its financial statements and exhibits. The filing includes various graphic files, likely presentation slides, and XBRL data, indicating a disclosure of information to the public. No specific financial figures or significant eve
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bearish, 45 neutral, 2 mixed. The dominant filing sentiment for Pulse Biosciences, Inc. is neutral.
Filing Type Overview
Pulse Biosciences, Inc. (PLSE) has filed 37 8-K, 6 10-Q, 3 DEF 14A, 1 10-K/A, 2 10-K, 1 SC 13D/A with the SEC between Mar 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PLSE's 42 recent filings, 3 were flagged as high-risk, 18 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $86,000 |
| Net Income | ($55,348,000) |
| EPS | ($0.82) |
| Debt-to-Equity | 0.17 |
| Cash Position | $95,214,000 |
| Operating Margin | -60.6% |
| Total Assets | $108,765,000 |
| Total Debt | $16,071,000 |
Key Executives
- Paul A. LaViolette
- Jon Skinner
- Dr. Darrin Uecker
- Kevin L. Trulock
- Darrin R. Uecker
- Sarah G. Bohannon
- Kevin L. Richardson
- Kevin L. Johnson
- Robert W. Duggan
- Adam W. Finerman, Esq.
- Kevin J. O'Malley
- Sarah M. Gleason
Industry Context
Pulse Biosciences operates in the highly competitive medical device sector, focusing on novel energy-based therapies. The company's Nano-pulse Stimulation (NPS) technology aims to disrupt established treatments in areas like cardiac ablation and soft tissue surgery. Key trends include the demand for less invasive procedures and advanced therapeutic solutions, but also significant R&D investment requirements and long regulatory pathways.
Top Tags
8-K (8) · financials (7) · 8-k (7) · sec-filing (5) · financial-statements (4) · filing (4) · Biotechnology (3) · SEC Filing (3) · leadership-change (3) · executive-appointment (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product Revenue | $86K | First reported product revenue for Q3 and YTD 2025, up from $0 in 2024. |
| Net Loss (YTD) | ($55.348M) | Increased from ($34.200M) in YTD 2024, indicating widening losses. |
| R&D Expenses (YTD) | $33.794M | Increased from $21.674M in YTD 2024, reflecting significant investment. |
| SG&A Expenses (YTD) | $24.699M | Increased from $14.322M in YTD 2024, showing higher operational costs. |
| Cash and Cash Equivalents | $95.214M | Decreased from $118.038M at Dec 31, 2024, indicating substantial cash burn. |
| Net Cash Used in Operations (YTD) | ($39.367M) | Increased from ($27.199M) in YTD 2024, highlighting accelerating cash outflow. |
| Common Shares Outstanding | 67,738 | Increased from 65,926 at Dec 31, 2024, indicating potential dilution. |
| Interest Income (Q3) | $1,001K | Slightly up from $976K in Q3 2024, providing some offset to losses. |
| Number of directors to be elected | 6 | Nominees for election to hold office until the 2026 annual meeting |
| Recommended frequency for advisory votes on executive compensation | 3 YEARS | Board's preference for future advisory stockholder votes |
| Shares of common stock outstanding | 67,757,578 | Total shares entitled to vote as of the October 22, 2025 record date |
| Shares required for a quorum | 33,878,790 | Majority of outstanding shares needed to constitute a quorum at the Annual Meeting |
| Annual Meeting Date | December 9, 2025 | Date the 2025 Annual Meeting of Stockholders will be held |
| Record Date | October 22, 2025 | Date by which stockholders must hold shares to vote at the Annual Meeting |
| Voting Deadline | 11:59 p.m., Eastern Time, on December 8, 2025 | Last time to submit votes by telephone or internet |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Pulse Biosciences, Inc. (PLSE)?
Pulse Biosciences, Inc. has 50 recent SEC filings from Mar 2024 to May 2026, including 37 8-K, 6 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PLSE filings?
Across 50 filings, the sentiment breakdown is: 3 bearish, 45 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Pulse Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Pulse Biosciences, Inc. (PLSE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Pulse Biosciences, Inc.?
Key financial highlights from Pulse Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PLSE?
The investment thesis for PLSE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Pulse Biosciences, Inc.?
Key executives identified across Pulse Biosciences, Inc.'s filings include Paul A. LaViolette, Jon Skinner, Dr. Darrin Uecker, Kevin L. Trulock, Darrin R. Uecker and 7 others.
What are the main risk factors for Pulse Biosciences, Inc. stock?
Of PLSE's 42 assessed filings, 3 were flagged high-risk, 18 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Pulse Biosciences, Inc.?
Forward guidance and predictions for Pulse Biosciences, Inc. are extracted from SEC filings as they are enriched.